Compare AMST & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMST | PMCB |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 6.3M |
| IPO Year | 2020 | 2001 |
| Metric | AMST | PMCB |
|---|---|---|
| Price | $0.88 | $0.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 74.7K | ★ 254.5K |
| Earning Date | 10-27-2026 | 09-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.83 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $364,777.00 | N/A |
| Revenue This Year | $19,089.81 | N/A |
| Revenue Next Year | $22.86 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 230.24 | N/A |
| 52 Week Low | $0.77 | $0.33 |
| 52 Week High | $3.90 | $1.51 |
| Indicator | AMST | PMCB |
|---|---|---|
| Relative Strength Index (RSI) | 37.17 | 34.43 |
| Support Level | $0.77 | $0.33 |
| Resistance Level | $1.11 | $0.85 |
| Average True Range (ATR) | 0.04 | 0.03 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 25.56 | 15.68 |
Amesite Inc is a technology company focused on building and commercializing AI (artificial intelligence)-powered solutions for the enterprise and for professionals, with particular emphasis on the post-acute healthcare market. It operates through two product lines: NurseMagic and LynkMagic. NurseMagic solutions include a B2B (business-to-business) enterprise application and a B2C (business-to-consumer) solution for individual healthcare professionals. LynkMagic provides enterprise AI solutions for healthcare and related organizations. Its products support documentation, workflow, compliance, oversight, and are designed to improve operational quality and efficiency. It has one single operating and reporting segment, B2C and B2B AI-driven solutions.
PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.